Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antipseudomonal/nausea
Lyen an sove nan clipboard la
8 rezilta yo
Cefsulodin treatment for serious Pseudomonas aeruginosa infections.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Cefsulodin, a narrow-spectrum cephalosporin with excellent antipseudomonal activity was used to treat 48 patients with 51 Pseudomonas aeruginosa infections. These included osteomyelitis, infected prostheses, post-operative and post-traumatic superficial wounds, decubitus and stasis ulcers, lower
Cefsulodin.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The chemistry, microbiology, pharmacokinetics, adverse reactions, and clinical indications for cefsulodin are reviewed and compared to ceftazidime and cefoperazone. Cefsulodin is a narrow-spectrum, third-generation cephalosporin with activity virtually restricted to Pseudomonas aeruginosa.
Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Doripenem is the latest carbapenem on the market to date. Although not an antibiotic in a new class, it offers a glimmer of hope in combating serious infections secondary to multidrug-resistant Gram-negative bacteria when we have not seen a new class of antibacterial, particularly for Gram-negative
Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
The increased prevalence of multi-drug resistant strains of P.aeruginosa and allergic reactions among adult patients with cystic fibrosis (CF) limits the number of antibiotics available to treat pulmonary exacerbations. Fosfomycin, a unique broad spectrum bactericidal antibiotic, might
Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Tigecycline, the first in a new class of glycylcyclines, has been approved for the treatment of complicated skin and skin structure and intraabdominal infections in adults. However, clinical data on its safety and effectiveness in cancer patients are lacking. We reviewed the records of all cancer
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Introduction: Ceftazidime-avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam.
Objectives:
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in patients with haematological malignancies until neutrophil recovery could prolong the therapy unnecessarily. We aimed to establish whether EAT discontinuation driven by a clinical approach regardless of
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Ceftolozane/tazobactam is a novel antipseudomonal β-lactam/β-lactamase inhibitor combination that is currently approved by the United States Food and Drug Administration for the treatment of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI). It exhibits
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
